Clinuvel Pharmaceuticals Limited (FRA:UR9)

Market Cap	325.05M -9.3%
Revenue (ttm)	53.04M +7.8%
Net Income	20.19M +1.5%
EPS	0.40 +2.9%
Shares Out	n/a
PE Ratio	16.10
Forward PE	14.87
Dividend	0.03 (0.40%)
Ex-Dividend Date	Sep 4, 2025

Volume	500
Average Volume	1,141
Open	6.25
Previous Close	6.51
Day's Range	6.25 - 6.50
52-Week Range	4.80 - 7.68
Beta	n/a
RSI	34.57
Earnings Date	Feb 23, 2026

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 16
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UR9

Financial Performance

In 2025, Clinuvel Pharmaceuticals's revenue was 95.02 million, an increase of 7.76% compared to the previous year's 88.18 million. Earnings were 36.17 million, an increase of 1.50%.

Financial numbers in AUD